Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323736 | 1.00 | KMT2A (0.45) | KMT2AMEN1MMP1MMP2MMP9 | |
| SCHEMBL323735 | 1.00 | KMT2A (0.45) | KMT2AMEN1MMP1MMP2MMP9 | |
| SCHEMBL29364700 | 1.00 | KMT2A (0.45) | KMT2AMEN1MMP1MMP2MMP9 | |
| SCHEMBL2081536 | 0.85 | KMT2A (0.47) | KMT2AMEN1CA1CA2LMNA | |
| SCHEMBL7587366 | 0.85 | KMT2A (0.47) | KMT2AMEN1CA1CA2LMNA | |
| SCHEMBL10254866 | 0.85 | KMT2A (0.44) | KMT2AMEN1MMP1MMP2MMP9 | |
| SCHEMBL2325747 | 0.85 | KMT2A (0.47) | KMT2AMEN1CA1CA2LMNA | |
| SCHEMBL3089042 | 0.85 | KMT2A (0.49) | KMT2AMEN1LMNAGAASTAT3 | |
| SCHEMBL10012108 | 0.85 | KMT2A (0.46) | KMT2AMEN1MMP1MMP2MMP9 | |
| SCHEMBL10012543 | 0.85 | KMT2A (0.48) | KMT2AMEN1CA2LMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068090-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2025-04-03 | — | — | WO | disclosed |
| US-12221425-B2 | Process for the preparation of CIC-1 chloride channel inhibitors | NMD PHARMA A/S (DK) | 2025-02-11 | — | — | US | disclosed |
| EP-3986878-B1 | PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS | NMD PHARMA AS (DK) | 2024-09-25 | — | — | EP | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| EP-4126819-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220298124-A1 | PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS | NMD PHARMA A/S (DK) | 2022-09-22 | — | — | US | disclosed |
| EP-3986878-A1 | PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS | NMD Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3347361-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180327420-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-11-15 | — | — | US | disclosed |
| US-20090264473-A1 | Novel Crystalline Forms of Antidiabetic Compounds | MERCK SHARP & DOHME CORP. | 2009-10-22 | — | — | US | disclosed |
| US-20090012151-A1 | Novel Compounds 951 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012151-A1 | Novel Compounds 951 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| WO-2009004379-A1 | NOVEL COMPOUNDS 951: A BIPHENYLOXYPROPANOIC ACID AS CRTH2 MODULATOR AND INTERMEDIATES | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | MERCK SHARP & DOHME LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | MERCK SHARP & DOHME LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080132480-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB S.A. (BE) | 2008-01-10 | — | — | US | disclosed |
| WO-2007103252-A2 | NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1806339-A1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB, S.A. (BE) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | PIK3CA, PIK3CD, PIK3CB | KMT2A 3406/4885MEN1 2518/4885MMP1 2306/4885 |
| US-20080132480-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | CYP26A1, CYP1A1, GPBAR1 | KMT2A 1697/4885MEN1 4025/4885MMP1 1592/4885 |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | CYP2F1, CYP3A5, SULT1E1 | KMT2A 490/4885MEN1 3560/4885MMP1 3067/4885 |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | PPARG, PPARA, FABP4 | KMT2A 1898/4885MEN1 4873/4885MMP1 4116/4885 |
| US-20090264473-A1 | Novel Crystalline Forms of Antidiabetic Compounds | PPARG, FFAR2, PPARA | KMT2A 1972/4885MEN1 4857/4885MMP1 3265/4885 |
| US-20220298124-A1 | PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS | CLIC1, CLCN2, CLIC4 | KMT2A 2873/4885MEN1 1349/4885MMP1 1472/4885 |
| US-20180327420-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | KMT2A 3406/4885MEN1 2518/4885MMP1 2306/4885 |
| US-20090012151-A1 | Novel Compounds 951 | HRH4, HRH1, HRH2 | KMT2A 3274/4885MEN1 3633/4885MMP1 2245/4885 |
| US-12221425-B2 | Process for the preparation of CIC-1 chloride channel inhibitors | CLIC1, CACNA1D, CLIC4 | KMT2A 3351/4885MEN1 1522/4885MMP1 1436/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | KMT2A 3088/4885MEN1 2260/4885MMP1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.